Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Antiretroviral Treatment Interruption(ATI) Study to Evaluate the Impact and Durability of AGT103-T to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy(ART) in Participants With Human Immunodeficiency Virus(HIV) Previously Treated With AGT103-T

NCT05540964 is registered in ClinicalTrials.gov with American Gene Technologies International Inc. as lead sponsor.

NCT NCT05540964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05540964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Antiretroviral Treatment Interruption(ATI) Study to Evaluate the Impact and Durability of AGT103-T to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy(ART) in Participants With Human Immunodeficiency Virus(HIV) Previously Treated With AGT103-T
Lead sponsor
American Gene Technologies International Inc.
Phase
Observational
Overall status
Unknown status
Start date
July 19, 2022
Completion date
July 19, 2025
Enrollment
7 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv